S
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a next-generation PD-1-inhibiting cytokine, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
Investor insights
Funding rounds participated in
$317M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2010
Funding rounds raised
Total raised
$317M
from 1 investors over 1 rounds
S
SOTIO Biotech raised $317M on January 2, 2022
Investors: PPF Group